Table 7.
Association between combined detection of AXL and YAP expression in 81 NSCLC tissues and paracancer lung tissues and clinical features
| Clinicopathologic feature | n | YAPLow | YAPHigh | χ 2 | P | ||
|---|---|---|---|---|---|---|---|
|
| |||||||
| AXLLow | AXLHigh | AXLLow | AXLHigh | ||||
| Age | 1.65 | 0.6490 | |||||
| < 60 | 27 | 6 (25.00%) | 3 (27.27%) | 8 (38.10%) | 10 (40.00%) | ||
| ≥ 60 | 54 | 18 (75.00%) | 8 (72.73%) | 13 (61.90%) | 15 (60.00%) | ||
| Gender | 1.02 | 0.2210 | |||||
| Male | 60 | 20 (83.33%) | 8 (72.73%) | 12 (57.14%) | 20 (80.00%) | ||
| Female | 21 | 4 (16.67%) | 3 (27.27%) | 9 (42.86%) | 5 (20.00%) | ||
| Differentiation | 37.25 | < .0001 | |||||
| Medium-well differentiated | 38 | 20 (83.33%) | 6 (54.55%) | 8 (38.10%) | 4 (16.00%) | ||
| Poorly differentiated | 43 | 4 (16.67%) | 5 (45.45%) | 13 (61.90%) | 21 (84.00%) | ||
| Histological type | 1.41 | 0.7031 | |||||
| Squamous carcinoma | 42 | 12 (50.00%) | 6 (54.55%) | 9 (42.86%) | 15 (60.00%) | ||
| Adenocarcinoma | 39 | 12 (50.00%) | 5 (45.45%) | 12 (57.14%) | 10 (40.00%) | ||
| T stage | 20.67 | 0.0001 | |||||
| T1 | 12 | 6 (25.00%) | 2 (18.18%) | 3 (14.29%) | 1 (4.00%) | ||
| T2 | 44 | 18 (75.00%) | 7 (63.64%) | 10 (47.62%) | 9 (36.00%) | ||
| T3 | 18 | 0 (0.00%) | 2 (18.18%) | 6 (28.57%) | 10 (40.00%) | ||
| T4 | 7 | 0 (0.00%) | 0 (0.00%) | 2 (9.52%) | 5 (20.00%) | ||
| Pathological TNM stage | 56.17 | < .0001 | |||||
| I | 35 | 24 (100.00%) | 6 (54.55%) | 5 (23.81%) | 0 (0.00%) | ||
| II | 11 | 0 (0.00%) | 4 (36.36%) | 5 (23.81%) | 2 (8.00%) | ||
| III | 35 | 0 (0.00%) | 1 (9.09%) | 11 (52.38%) | 23 (92.00%) | ||
| IV | 0 | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||